Savient's New CEO Johnson Tasked With Turning Krystexxa Into A Commercial Success
This article was originally published in The Pink Sheet Daily
Executive Summary
Eli Lilly's oncology head John Johnson has been named to the top post at Savient Pharmaceuticals as the company tries to rebound from a failed sales attempt.